课题基金 / 基金详情

Novel Components of the mTORC1 and mTORC2 Pathways

Novel Components of the mTORC1 and mTORC2 Pathways
mTORC1 和 mTORC2 通路的新成分
批准号:
10114955
负责人:
JONATHAN S. WEISSMAN
金额:
$48.75万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-04-01 至 2022-04-30

项目摘要

项目成果

JONATHAN S. WEISSMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The mTOR kinase is the central component of a signaling pathway that controls mass accumulation and metabolism in response to the nutritional state of organisms. The pathway is deregulated in many common human diseases, including cancer, epilepsy, and diabetes, and is also well established to modulate the aging process. Pharmacological or genetic suppression of mTOR is amongst the best- validated approaches for increasing the lifespan of diverse organisms. The mTOR protein kinase is the target of the drug rapamycin and the catalytic subunit of two large protein complexes, mTOR Complex 1 (mTORC1) and 2 (mTORC2), that control separate branches of the pathway and preferentially respond to different stimuli. mTORC1 responds to diverse signals, including many types of growth factors, nutrients, and stresses, and regulates the balance between major anabolic and catabolic processes, including protein, nucleotide, and lipid synthesis as well as autophagy, respectively. Recently, we discovered many of the components through which mTORC1 senses nutrients and we are just starting to understand the role of the nutrient-sensing pathway in vivo. Our preliminary data show that the appropriate regulation of mTORC1 by nutrients is essential for mice to adapt to diets low in the essential amino acid leucine. Moreover, we have evidence that mTORC1 is spatially controlled in unexpected ways in tissues in vivo and that novel in vivo regulatory mechanisms remain to be discovered. The goals of our proposed work are to understand why the capacity of mTORC1 to sense leucine deprivation is important for mice to adapt to a leucine-free diet (Aim 1) and the role of compartmentalized nutrient sensing in the control of tissue physiology and metabolism (Aim 2). In addition, we will exploit in vivo proteomics and genetics to identify novel mTORC1 regulators in the liver (Aim 3). We will accomplish our goals with a multi-disciplinary approach that exploits biochemistry, metabolomics, proteomics, molecular biology, and mouse engineering. Our results should increase our understanding of a central growth regulator in vivo and reveal novel regulatory mechanisms that may have value as therapeutic targets.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.immuni.2017.06.005
发表时间: 2017-06-20
期刊: Immunity
影响因子: 32.4
作者: [Ersching J, Efeyan A, Mesin L, Jacobsen JT, Pasqual G, Grabiner BC, Dominguez-Sola D, Sabatini DM, Victora GD]
通讯作者: Victora GD
DOI: 10.1126/science.1207056
发表时间: 2011-11-04
期刊: Science (New York, N.Y.)
影响因子: --
作者: [Zoncu R, Bar-Peled L, Efeyan A, Wang S, Sancak Y, Sabatini DM]
通讯作者: Sabatini DM
DOI: 10.1016/j.cmet.2017.07.001
发表时间: 2017-08-01
期刊: Cell metabolism
影响因子: 29
作者: [Wolfson RL, Sabatini DM]
通讯作者: Sabatini DM
DOI: 10.1158/0008-5472.can-16-0155
发表时间: 2016-12-15
期刊: Cancer research
影响因子: 11.2
作者: [Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS]
通讯作者: Brugge JS
14
    Defining Molecular Signatures Underlying Lysosomal Dysfunction in Alzheimer’s Disease
    Exploiting mitochondrial heteroplasmy for cancer chemotherapy
    MASS SPECTROMETRY OF PROTEINS DERIVED FROM SHORT OPEN READING FRAME
    Cell Growth Signaling in Cancer Development
    海外基金